NeuraLight Biomarkers Outperform Traditional Measures in Tracking Parkinson's Disease Progression
NeuraLight Biomarkers Reveal What Parkinson's Gold-Standard Measurement Scale Misses in a Study Led by the Scale's Own Developers
Image: Businesswire
A multicenter study involving 280 Parkinson's patients across five countries found that NeuraLight biomarkers significantly outperformed the MDS-UPDRS, the standard measurement scale for Parkinson's disease. This advancement could enhance the detection of disease progression and improve the efficiency of clinical trials for potential therapies.
- 01NeuraLight's biomarkers demonstrated superior sensitivity in detecting Parkinson's disease progression compared to the MDS-UPDRS, which often misses subtle changes.
- 02The study was led by Prof. Olivier Rascol and Prof. Christopher G. Goetz, both developers of the MDS-UPDRS, highlighting the importance of the findings.
- 03NeuraLight's leading biomarker, ASH, showed significant deterioration in patients with a P-value of less than 0.0001, indicating strong reproducibility across clinical sites.
- 04The study followed patients in two trials: the PALOMA study across four countries and the PDHF study in Israel, confirming the biomarkers' effectiveness in diverse settings.
- 05NeuraLight's technology aims to improve the reliability of measuring Parkinson's disease progression, potentially leading to faster approval of effective therapies.
Advertisement
In-Article Ad
A recent peer-reviewed study published in *Pharmaceutical Medicine* revealed that NeuraLight biomarkers significantly outperform the MDS-UPDRS in tracking Parkinson's disease progression. Conducted across five countries with 280 patients, the study was led by Prof. Olivier Rascol and Prof. Christopher G. Goetz, both of whom contributed to the development of the MDS-UPDRS. The findings indicate that NeuraLight's biomarkers can detect changes in disease progression that the MDS-UPDRS often misses due to its reliance on subjective clinician scoring. One key biomarker, ASH (Amplitude of Saccadic Hypometria), provided objective measurements of eye movement, showing significant deterioration in patients, with a P-value of less than 0.0001. This consistent performance across various sites demonstrates the potential of NeuraLight's technology to enhance clinical trial efficiency and increase confidence in treatment effect detection. The study's results could lead to improved methodologies in Parkinson's disease-modifying trials, ultimately helping to identify effective therapies more reliably.
Advertisement
In-Article Ad
The study's findings could revolutionize how Parkinson's disease is monitored, leading to more effective clinical trials and potentially faster access to new therapies for patients.
Advertisement
In-Article Ad
Reader Poll
Do you believe that new biomarkers will improve Parkinson's disease treatment outcomes?
Connecting to poll...
Read the original article
Visit the source for the complete story.